Skip to main content
. 2023 Aug 8;46(10):961–974. doi: 10.1007/s40264-023-01338-9

Fig. 2.

Fig. 2

Study flow chart of participants enrollment, follow-up, and incidence of mass drug administration (MDA)-associated adverse events (AEs) in each treatment group. The incidence of experiencing one or more MDA-associated AEs is indicated in bold. DA diethylcarbamnzine + albendazole, DEC diethylcarbamazine citrate, IDA ivermectin + dethylcarbazine + albendazole